Supercharging A New FDA: Marty Makary on Science, Power & Patients
Episode Details
In an extensive interview with David Friedberg, FDA Commissioner Marty Makary details the ambitious agenda of FDA Reforms under the Donald Trump Administration. A core focus is accelerating the Drug Approval Process to shorten Clinical Trial Timelines and enhance the United States' competitiveness in the US-China Biotech Competition. Key strategies include reducing the default for Pivotal Trials from two to one, replacing animal studies with Computational Modeling and Organ on a chip technology, and adopting Bayesian Statistics for real-time data analysis. Makary envisions a future of Continuous Trials and is enhancing Post-market Surveillance with AI. He also reaffirms his strong support for the Right to Try law. The reforms extend to public health guidance. Makary criticizes the field of Nutrition Science for creating a 'failed' Food Pyramid and shifts the focus from fats to the dangers of Refined Carbohydrates, which he links to the Obesity Epidemic and widespread Insulin Resistance. The rise of GLP-1s is discussed as a therapeutic response. In another move to rebuild public trust, the administration has revised the national Vaccine Schedule, creating a prioritized list of Core Essential Vaccines that stands apart from broader CDC recommendations. Lowering Drug Prices is a top priority for President Donald Trump. Makary outlines a multi-pronged strategy including Most Favored Nation Status Pricing, accelerating the approval of Biosimilars to create competition for expensive Biologics, and a major initiative to move more drugs to Over-the-Counter Drugs status, bypassing the opaque system of PBMs (Pharmacy Benefit Managers). The agency is also cracking down on misleading Pharmaceutical Advertising. Makary, who previously worked at Johns Hopkins, is also steering a cultural shift at the NIH, criticizing the old guard, including Tony Fauci, and redirecting funds toward root cause research, such as the link between the Microbiome and conditions like Autism. The discussion, taking place during the JP Morgan Healthcare Conference in San Francisco, also touches on promising technologies like Cell and Gene Therapy and CARTT therapy, and sets a clear goal to find a cure for Type 1 Diabetes.
Key Topics & People
The global superpower whose foreign and domestic policies are the focus of the interview.
Former US President who maintains a strong base of supporters that Fetterman treats with respect.
Co-host of the All-In Podcast who interviewed Senator John Fetterman on various political and economic topics.
Major California city heavily criticized by Kalanick for excessive regulation, street alterations, and failing to protect its citizens.
An autoimmune disease where the body attacks insulin-producing beta cells, effectively halted in animal models in a recent study.
The executive branch of the U.S. government led by President Donald Trump, which is actively reforming agencies like the FDA and NIH.
A type of immunotherapy where a patient's T-cells are engineered to attack diseases like cancer and autoimmune conditions. It is described as an amazing and mind-boggling class of drugs.
Foods such as cellular meat or proteins made via fermentation, which the FDA regulates. Makary's administration is closing loopholes in the 'generally recognized as safe' (GRAS) process that affects these products.
The marketing of drugs directly to consumers, which the FDA is cracking down on to prevent misleading impressions and ensure a fair balance of information.
The community of microorganisms in the human gut, now recognized as a major frontier in medicine that influences brain health, mood, and potentially conditions like autism.
Advanced medical treatments that involve modifying a patient's cells or genes. The FDA is getting rid of certain regulatory requirements to accelerate their development.
A category of non-prescription medications. The FDA aims to move more drugs into this category to increase price transparency, competition, and access while bypassing PBMs.
A policy pursued by the Trump administration to ensure the US pays the lowest price for pharmaceuticals among developed nations, aiming to radically lower drug costs.
Generic versions of biologic drugs. The FDA is cutting the red tape for their approval to increase competition and lower drug prices.
A physiological condition, often driven by high carbohydrate intake, that is at the root of most chronic diseases like diabetes and heart disease.
A new, smaller, and prioritized list of recommended childhood vaccines (38 doses) created by the FDA to rebuild public trust and combat vaccine hesitancy.
The scientific field related to diet and health, which Marty Makary describes as one of the most corrupted fields, leading to flawed dietary guidance like the old Food Pyramid.
A class of food products that have been stripped of fiber and nutrients, identified as a primary driver of the obesity and diabetes epidemics in American children.
A major public health crisis in the United States, with 40-60% of the adult population being clinically obese. It's being addressed by both dietary changes and new drugs like GLP-1s.
The practice of monitoring the safety and efficacy of drugs after they have been approved and are in public use, which the FDA plans to enhance using big data and AI.
A proposed new paradigm for clinical research where data is monitored in real-time, rather than in discrete phases, to accelerate the drug development process.
A law, signed by President Trump, that allows patients with life-threatening diseases to access experimental treatments that have not yet received full FDA approval.
An advanced lab technique where human cells (e.g., liver or heart cells) are grown to test drug toxicity, serving as an alternative to animal studies.
A statistical method that allows for real-time analysis of clinical trial data, enabling faster identification of drug efficacy or safety signals. The FDA now allows its use.
A modern technique using computers to predict a drug's effects, which is being used by the FDA to reduce the need for animal testing.
The duration of Phase 1, 2, and 3 trials required for drug approval, which the FDA aims to shorten significantly through various reforms.
A prestigious university and hospital system where Marty Makary had a clinical practice and served on the faculty of the School of Public Health.
Large-scale (typically Phase 3) clinical trials required for drug approval. The FDA has changed the default requirement from two trials to one, a major cost and time-saving reform.
The multi-stage process, including clinical trials, for getting new drugs to market. The FDA is reforming this process to reduce the typical 10-12 year timeline.
A major economic and healthcare issue in the US. The Trump administration is taking steps to lower them through policies like Most Favored Nation pricing and promoting biosimilars.
The recommended timeline for childhood vaccinations. The FDA has revised this to a list of 'core essential vaccines' to rebuild public trust and align more with international standards.
A series of 42 major changes implemented by Marty Makary at the FDA to challenge the status quo, increase efficiency, and accelerate the approval of drugs and therapies.
Former director of the National Institute of Allergy and Infectious Diseases, mentioned as part of the old guard and culture at the NIH.
Considered the biggest and most important biotech conference globally, held in San Francisco.
The strategic rivalry between the United States and China for dominance in biopharma innovation, life sciences, and biomedical research.
The official dietary guidance chart which Makary's FDA has 'flipped upside down' to prioritize protein over a historical focus on carbohydrates, citing decades of flawed science and industry influence.
_(cropped).png?width=300){kind=avatar}
The current FDA Commissioner in the Trump administration, a surgeon from Johns Hopkins, and author, leading significant reforms at the agency.
.svg?width=300){kind=avatar}
Intermediaries in the drug supply chain that are criticized for contributing to high drug prices through opaque 'money games'.